EFFECT ·Filed Aug 13, 2026

CAMP

Camp4 Therapeutics Corp
NEUTRAL
Impact 3/10
Horizonweeks Processed1mo ago SEC9999999995-26-002650
IPO/offering going effective
Actionable Insight • Neutral

Monitor for any subsequent prospectus supplements or takedown announcements from the shelf, which would signal an actual capital raise and potential dilution. The shelf's effectiveness is a necessary precursor to any offering, but does not itself move the stock.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d
CAMP ▼ -5.56% at T+20d
NEUTRAL call ✗ call lost -5.56% · α vs SPY -3.81% · entry $4.50 → $4.25
Next anchor: T+60d in 5w
Latest observation: T+32 -8.35% FF3 residual α
Entry anchored
Aug 12, 05:59 PM ET
via 1-min bar
T+1d
+20.89%
call +20.89% · α +21.09%
$5.44
settled 7w ago
T+5d
-1.11%
call -1.11% · α +0.85%
$4.45
settled 6w ago
T+20d
-5.56%
call -5.56% · α -3.81%
$4.25
settled 21d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

Camp4 Therapeutics Corp's S-3 shelf registration statement (File No. 333-298067) was declared effective by the SEC on August 12, 2026. This allows the company to offer and sell securities (common stock, preferred stock, debt, warrants, or units) from time to time at its discretion, creating a potential dilution overhang for existing common shareholders. The effectiveness itself is a routine procedural step, but it opens the door for future capital raises that could pressure the stock.

Key Facts

  • S-3 shelf registration became effective on August 12, 2026.
  • Company can now offer and sell various securities (common stock, preferred stock, debt, warrants, units) at its discretion.
  • File Number: 333-298067.
  • The shelf registration creates a potential dilution overhang for common shareholders.

Financial Impact

No immediate financial impact. The shelf registration enables future capital raises of an undisclosed amount, which could be dilutive to existing shareholders if common stock is issued.

dilution

Risk Factors

  • Potential future dilution from share issuance under the shelf.
  • Uncertainty about the timing and size of any future offering.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002650
Document: 9999999995-26-002650-index.html9999999995-26-002650
Document: 9999999995-26-002650.txt9999999995-26-002650
13 reports for CAMP
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+1▲ +49.40%Mar 5, 2026
Filters
Rows
Reports for CAMP — sortable, filterable
TypeNow
Sep 10, 2026
22d ago
Press Release
NEUTRAL ★ 4/10
$4.34 $4.03▼ −7.14%▼ −6.64%$3.73 (−13.95%)
Sep 2, 2026
29d ago
Insider Cluster
NEUTRAL ★ 3/10
$4.49 $4.25▼ −5.35%▼ −4.20%$3.73 (−16.83%)
Aug 21, 2026
6w ago
Insider Cluster
BEARISH ★ 4/10
$4.48 $4.15▲ +7.37%▲ +7.84%$3.73 (+16.64%)
Aug 13, 2026
7w ago
EFFECT
NEUTRAL ★ 3/10
$4.50 $4.45▼ −1.11%▲ +0.85%$3.73 (−17.01%)
Aug 5, 2026
8w ago
Insider Cluster
BULLISH ★ 8/10
$4.50 $4.50· 0.00%▼ −1.21%$3.73 (−17.01%)
Aug 5, 2026
8w ago
Insider Cluster
BULLISH ★ 8/10
$4.50 $4.50· 0.00%▼ −1.21%$3.73 (−17.01%)
Jul 27, 2026
9w ago
8-K
MIXED ★ 6/10
$3.42 $3.45▲ +0.88%▼ −0.20%$3.73 (+9.20%)
Jun 19, 2026
14w ago
Press Release
NEUTRAL ★ 2/10
$4.20 $4.20· 0.00%▲ +2.07%$3.73 (−11.08%)
Jun 12, 2026
15w ago
8-K
NEUTRAL ★ 3/10
$3.96 $4.20▲ +6.06%▲ +7.44%$3.73 (−5.69%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$4.22 $4.14▼ −1.90%▼ −2.33%$3.73 (−11.50%)
Showing 10 of 13

US Market Status

Market Open — Closes in 3h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access